The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes. Herring RA, Shojaee-Moradie F, Stevenage M, Parsons I, et al. Diabetes Care 2022 Mar 21. pii: 144845. doi: 10.2337/dc21-2043.

Read + Share

Amedeo Smart

Independent Medical Education

Herring RA, Shojaee-Moradie F, Stevenage M, Parsons I, et al. The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes. Diabetes Care 2022 Mar 21. pii: 144845. doi: 10.2337/dc21-2043.
PMID: 35312749